[Longterm therapy and etofibrate (author's transl)].

Abstract

The stabilization parameters of patients under routine care are differentiated. 20 hyperlipoproteinemic patients (types IIa, IIb and IV) who were difficult to stabilize were treated with 0.9 g etofibrate daily. In addition to the cholesterold and triglyceride levels, we followed up the laboratory control parameters in the serum, fasting blood sugar and differential blood count. During the treatment period the cholesterol levels fell to 18%, triglycerides to 50%. Tachyphylaxis was never seen. The good tolerance of etofibrate shows that the substance is suitable as a potent hypolipidemic agent for longterm treatment of hyperlipoproteinemia.

• Authors: H Kaffarnik, J Schneider, R Schubotz, P Zöfel
• Journal: MMW, Munchener medizinische Wochenschrift (MMW Munch Med Wochenschr) Vol. 122 Issue 3 Pg. 95-8 (Jan 18 1980) ISSN: 0341-3098 [Print] Germany
• Vernacular Title: Langzeittherapie mit Etofibrat.
• PMID: 6767931 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anticholesteremic Agents
• Blood Glucose
• Triglycerides
• etofibrate
• Clofibric Acid
• Clofibrate

Topics

• Anticholesteremic Agents (therapeutic use)
• Blood Cell Count
• Blood Glucose (analysis)
• Clofibrate (analogs & derivatives)
• Clofibric Acid (analogs & derivatives, therapeutic use)
• Drug Administration Schedule
• Drug Tolerance
• Humans
• Hyperlipoproteinemias (drug therapy)
• Triglycerides (blood)